Effect of benzbromarone on body fat in patients with gout
10.3760/cma.j.cn311282-20200304-00126
- VernacularTitle:苯溴马隆对痛风患者体脂的影响
- Author:
Ruyi LI
1
;
Yuwei HE
;
Zhen LIU
;
Lingling CUI
;
Xiaomei XUE
;
Ting ZHAO
;
Xinde LI
;
Changgui LI
Author Information
1. 青岛大学附属医院内分泌与代谢性疾病科 266003
- From:
Chinese Journal of Endocrinology and Metabolism
2020;36(5):410-415
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of urate-lowering therapy (ULT) on body fat and visceral fat areas in patients with gout and to analyze the related risk factors.Methods:A total of 140 patients with gout eligible for enrollment were recruited from the gout clinic in the Affiliated Hospital of Qingdao University from Sept. 2018 to Sept. 2019. After 2 weeks of washout, all patients were treated with benzbromarone for consecutive 12 weeks. The data of blood biochemical, body fat (BF), body fat percentage (BFP) and visceral fat area (VFA) were collected, and the differences before and after ULT as well as the risk factors affecting the changes of BF, BFP, and VFA were analyzed.Results:The diastolic blood pressure (DBP), alanine aminotransferase (ALT), serum uric acid (sUA), BF, BFP, and VFA were significantly decreased after ULT ( P<0.05). The results of multivariate stepwise linear regression analysis showed that sUA, creatinine (Cr) and glomerular filtration rate (eGFR) were independent risk factors affecting the improvement of BF and VFA (P<0.05). Lower serum uric acid levels in patients with gout before and after ULT indicated better improvement effect of body fat and visceral fat areas( P<0.05). Conclusion:Gout combined with hyperuricemia is closely related to visceral obesity. In addition to lowering the serum uric acid level, ULT could also benefit the body fat and visceral fat area in patients with gout to some extent.
